Sign in Subscribe
Stock offerings

Ocugen Closes Registered Direct Offering, Secures $50 Million in Funding

Strategic Insights

— 2 min read

Ocugen, a pioneering biotechnology leader in gene therapies for blindness diseases, has successfully closed its registered direct offering, securing $50 million in funding. The company announced the closing of its previously announced offering to Janus Henderson Investors, which consisted of 20 million shares of common stock and warrants to purchase up to 20 million shares of common stock. The gross proceeds to Ocugen were approximately $20 million, with the potential for up to $30 million more if the warrants are exercised in full.

Key Takeaways:

  • Ocugen has secured $50 million in funding through the registered direct offering, which is expected to extend the company's cash runway into the first quarter of 2027.
  • The company's breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations.
  • Ocugen has programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy – late stage dry age-related macular degeneration.
  • The company's gene-agnostic approach and modifier gene therapies have the potential to address complex diseases caused by imbalances in multiple gene networks.
  • Ocugen has filed a prospectus supplement with the SEC, and copies are available on the SEC's website or from Noble Capital Markets, Inc.
  • The company's cash runway is expected to extend through the second quarter of 2026 without warrant exercise, and into the first quarter of 2027 with combined offering proceeds and warrant exercise.
  • The offering was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-278774) previously filed with the SEC on May 1, 2024.

Statistics:

  • 20,000,000 shares of common stock and warrants to purchase up to 20,000,000 shares of common stock were purchased by Janus Henderson Investors.
  • The gross proceeds to Ocugen were approximately $20 million before deducting placement agent fees and other estimated offering expenses.
  • The company may receive up to $30 million more if the warrants are exercised in full.
  • The expected cash runway extension is into the first quarter of 2027 with combined offering proceeds and warrant exercise.
  • The company has programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe.

Sources:

  • GLOBE NEWSWIRE, "Ocugen, Inc. Closes $50 Million Registered Direct Offering" (August 12, 2025)
  • SEC Filing, Form S-3 (File No. 333-278774), declared effective on May 1, 2024
  • Ocugen, Inc. press release, "Ocugen, Inc. Announces Closing of Registered Direct Offering" (August 12, 2025)

Read more